This study is in progress, not accepting new patients
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Sarah Larson
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Sarah Larson
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 19 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- Related info
- ID
- NCT03539744
- Phase
- Phase 3 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- About 265 people participating
- Last Updated